Alto Neuroscience: $45 Million Raised To Pioneer Precision Psychiatry By Developing Targeted Medicines
By Amit Chowdhry ● Dec 1, 2023
Alto Neuroscience recently announced an oversubscribed $45 million Series C financing. This funding round was led by InVivium Capital, with participation from additional new investors Franklin Templeton, Point72, Eli Lilly and Company, and Alexandria Venture Investments. And existing investors Alpha Wave Ventures, Lightswitch Capital, partners of Alkeon Capital, WhatIf Ventures, and Windham Venture Partners also participated in the financing.